Arrhythmogenic right ventricular dysplasia endomyocardial biopsy

Arrhythmogenic right ventricular dysplasia Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Arrhythmogenic right ventricular dysplasia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
X - Ray
ECG
Cardiac MRI
Echocardiogram
Other Imaging Findings
Endomyocardial biopsy
Atuopsy
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Arrhythmogenic right ventricular dysplasia endomyocardial biopsy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Arrhythmogenic right ventricular dysplasia endomyocardial biopsy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
National Guidelines Clearinghouse
NICE Guidance
FDA on Arrhythmogenic right ventricular dysplasia endomyocardial biopsy
CDC on Arrhythmogenic right ventricular dysplasia endomyocardial biopsy
Arrhythmogenic right ventricular dysplasia endomyocardial biopsy in the news
Blogs onArrhythmogenic right ventricular dysplasia endomyocardial biopsy
Directions to Hospitals Treating Arrhythmogenic right ventricular dysplasia
Risk calculators and risk factors for Arrhythmogenic right ventricular dysplasia endomyocardial biopsy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Transvenous biopsy of the right ventricle can be highly specific for ARVD, but it has low sensitivity. False positives include other conditions with fatty infiltration of the ventricle, such as chronic alcohol abuse and Duchenne/Becker muscular dystrophy.

False negatives are common, however, because the disease progresses typically from the epicardium to the endocardium (with the biopsy sample coming from the endocardium), and the segmental nature of the disease. Also, due to the paper-thin right ventricular free wall that is common in this disease process, most biopsy samples are taken from the ventricular septum, which is commonly not involved in the disease process.

A biopsy sample that is consistent with ARVD would have > 3% fat, >40% fibrous tissue, and <45% myocytes.